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The history of IVM of mammalian oocytes, especially of human oocytes, holds a special 
place for Robert Edwards.  He was the first to comprehensively examine and demonstrate 
maturation of human oocytes in vitro and in so doing he changed the course of medicine by 16 
fertilising them in vitro. In reviewing his contribution, we have examined the state of the field 
at the time and discuss his pioneering insights into mammalian oocyte biology. We will also 
discuss how some of the major concepts and challenges identified by Edwards 50 years ago 





In vitro maturation (IVM) of oocytes is a technique that has always offered great promise for 
maximising the potential uses of the female gamete.  It offers opportunities to preserve 
fertility and treat infertility in women, especially those that are unable to access 
gonadotrophin treatment for ovarian hyperstimulation, due to ovarian hypersensitivity, cost or 28 
other social reasons. Oocyte IVM is widely employed in animal breeding, primarily to 
increase genetic selection or introduce diversity in farmed and companion animal species, 
and to a lesser extent, IVM is used in the conservation of rare breeds and species.  All of 
these potential future applications of IVM were recognized by Edwards in his landmark 1965 32 
Nature publication (Edwards, 1965b).  IVM is simple in concept and is elegantly described 
2 
 
by Edwards in 1962; here in the context of discussing the practical benefit of IVM compared 
with in vivo endocrinological manipulation of oocyte maturation: 
 36 
“Fortunately, there is an alternative technique which promises to supersede the 
endocrinological control of ovulation in most species. This is to stimulate the 
oocytes directly in vitro after their liberation from the follicle. In addition to being 
a most attractive technique in that it avoids the use of hormone injections in vivo 40 
and permits the use of small pieces of ovary, it has also proved to be an unusually 
simple technique when used in several species. All that is necessary is to liberate 
the oocytes into a simple culture medium by puncturing the follicles; many 
oocytes then immediately resume their maturation” (Edwards, 1962). 44 
 
This definition of IVM remains relevant even today, just as it was when first described by 
Pincus and Enzmann (Pincus and Enzmann, 1935). Notably, the procedure described above, 
is still the practice used universally in domestic animal and veterinary IVM. However, in the 48 
human reproductive medicine sphere, IVM terminology has become decidedly opaque over 
the past decade or more; the term IVM has been used variably to describe the culture of 
completely immature (germinal vesicle, GV-stage) oocytes from unstimulated ovaries (as 
defined above), or oocytes of mixed meiotic status following a range of ovarian 52 
hyperstimulation regimes, or, even more concerning, used to describe the culture of arrested 
immature GV oocytes recovered from hyperstimulated cycles (“Rescue IVM”). It is well 
documented that embryos generated from Rescue IVM oocytes are genetically abnormal 
(Nogueira et al., 2000; Jones et al., 2008). This confusion in IVM terminologies requires 56 
resolution by the discipline. For the purposes of this review, we will use the understanding of 
IVM as founded by both Pincus and Edwards (Pincus and Enzmann, 1935; Edwards, 1962), 
which is the in vitro maturation of immature, GV-stage, cumulus-oocyte complexes (COCs) 
collected from antral follicles of unstimulated ovaries.  60 
 
Oocytes readily reach metaphase II (MII) of meiosis spontaneously in vitro (i.e. without 
hormonal stimulation), and MII oocytes can be fertilized for immediate embryo production or 
alternatively, mature oocytes can be stored by vitrification in liquid nitrogen for later use.  64 
IVM is practiced widely for commercial breeding opportunities in beef and dairy cattle, 
where global production of IVM-derived embryos is approaching half a million each year 
(Stroud, 2012).  It is also sufficiently successful for practical purposes in other species, such 
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as sheep, deer, goats, pigs, cats and mice.  In contrast, IVM is difficult in primates and its 68 
application in human reproductive medicine has been limited.  This is largely due to the 
poorer outcomes relative to gonadotrophin treated, traditional IVF cycles. This includes 
poorer oocyte maturation rates, implantation rates, increased miscarriage rates and therefore 
poorer pregnancy outcomes per cycle initiated (Gilchrist et al., 2011).  Today, human clinical 72 
IVM occupies a niche role in providing a treatment option for women with polycystic ovaries, 
fertility preservation for cancer patients and also as a cheaper and simpler alternative to IVF 
which has proved attractive in developing countries particularly in East Asia.  
 76 
IVM prior to the 1960’s 
 
IVM as we recognize it today was first reported by Pincus and Enzmann (Pincus and 
Enzmann, 1935).  They made a number of observations about the spontaneous nature of 80 
meiosis when rabbit ova were removed from antral follicles. They carefully described events 
such as germinal vesicle breakdown (GVBD) and MII formation during in vivo oocyte 
maturation and noted that these events were mirrored in vitro, without the need for 
supplemental hormones.  Pincus and Saunders (Pincus and Saunders, 1939) made similar 84 
observations with human oocytes.  In both publications, oocytes were inseminated in vitro in 
an attempt to fertilize them.  This was pronounced as successfully achieved, but later 
questioned by others as dubious, as there was no supporting evidence that sperm capacitation 
had occurred (as discussed in Biggers; (Biggers, 2012)).  As experienced by Edwards in later 88 
years, Gregory Pincus was increasingly criticised in the media of the time for his work on 
maturing human oocytes in vitro and attempting to fertilize them.  By 1939, in the briefest of 
letters to the journal Science, he announced he was withdrawing his activity from the area:  
“In certain press reports of a recent paper on meiosis in explanted human 92 
ovarian ova, the statement has appeared that I plan to carry on this work to the 
extent of attempting to discover if human offspring can be produced by the 
methods that we employ in ovum culture.  This statement is incorrect. My work 
with human ova ended with these studies of maturation and I have no intention 96 
whatsoever to continue them” (Pincus, 1939). 
In the intervening years prior to the 1960’s, attention shifted away from IVM itself to the 
challenges of fertilizing mature oocytes and the discoveries made surrounding sperm 
capacitation and subsequent embryo development (see companion reviews in this series).  100 
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Nevertheless, Chang (Chang, 1955) provided confirmatory evidence to support Pincus and 
Enzmann’s original observations of the timing of meiosis in rabbit oocytes during IVM (9-11 
hours to reach MII), and that this occurred independent of any hormonal treatment.  He also 
found that if neat follicular fluid was used to mature oocytes, instead of diluted serum, 104 
progression of MII was delayed “probably due to the presence of an inhibiting factor in the 
follicular fluid of the unmated rabbit” (Chang, 1955), a concept that is uncannily relevant 
today with the current significant interest in delaying oocyte meiosis during IVM.   
 108 
Robert Edwards’ contribution to IVM 
 
In the late 1950’s, Edwards’ interest and considerable expertise were in the areas of the 
genetics of aneuploidy in oocytes, oocyte meiosis and superovulation of mice (Johnson, 112 
2011).  Although he had been at the forefront of developing gonadotrophin treatments to 
induce multiple ovulation and pregnancies and he recognized the capacity of exogenous 
gonadotrophin treatments to deliver oocytes at all stages of meiosis, nonetheless he became 
interested in determining if he could establish an in vitro system to examine meiotic 116 
progression in human oocytes, as he noted that to do so using exogenous hormonal regulation 
would be “…difficult to apply” (Edwards, 1962).   
 
Edwards’ contribution to IVM principally lies within three reports in the journal Nature 120 
(Edwards, 1962; Edwards, 1965b; Edwards et al., 1969) and associated Lancet paper 
(Edwards, 1965a).  The 1965 Nature publication remains one of the seminal contributions to 
the field of IVM and is his 2
nd
 most cited publication behind the 1978 Lancet publication 
announcing the birth of Louise Brown (Steptoe and Edwards, 1978).  Edwards’ work on IVM 124 
was largely restricted to the decade of the 1960’s, and can be roughly divided into two halves; 
the first half of the 1960’s where he focused on achieving meiotic maturation of animal and 
human oocytes using IVM, and in the late 1960’s, where he focused intensely on achieving 
fertilisation in vitro of the IVM oocytes. It is noteworthy that, unlike much of his subsequent  128 
scientific career, during this early period of the 1960’s, he largely worked alone and was 
responsible for driving the direction of his research, overcoming substantial barriers to access 
research tissues (especially human), and performing the experiments himself with support 
from his staff.  Perhaps as a consequence, Edwards was particularly passionate about oocyte 132 




The first report, published on November 3rd 1962 (Edwards, 1962), demonstrated that 
spontaneous oocyte maturation was at least initiated (GVBD) in vitro in several species 136 
(mouse, rat, hamster, monkey), although it seems he only cultured the rodent oocytes in vitro 
for 6-8 hours, most likely taking the timing of rabbit IVM described earlier by others (Pincus 
and Enzmann, 1935; Chang, 1955).  Other species attempted in this study were dog, baboon 
and human, of which there was little evidence of GVBD in vitro, probably as he was too 140 
hasty to examine evidence of maturation (for example, he only allowed 20 hours of IVM for 
human oocytes).  Nevertheless, he correctly asserted that oocytes, if already denuded of 
somatic cells when liberated from follicles and/or already displayed condensed chromatin or 
a polar body, were likely derived from atretic follicles (Edwards, 1962).   144 
 
By the early 1960’s, superovulation technologies in animals, but not humans, were well 
advanced and Edwards had considerable experience with the kinetics of oocyte meiosis in 
vivo in a variety of animals, based on the timing of human chorionic gonadotrophin (hCG) 148 
administration. With great insight, he reasoned that the differing kinetics of meiosis across 
different species in vivo may be paralleled by differing and species-specific meiotic kinetics 
in vitro. The time required for human oocyte maturation was unknown.  In the more heralded 
1965 paper (Edwards, 1965b), he extended the culture time for human IVM. With each failed 152 
attempt he further extended the culture duration until eventually he witnessed GVBD of a 
human oocyte at 28 hours of IVM.  This was a truly triumphant moment for Edwards, as he 
recounts in his book: 
 156 
“The next four hours passed slowly, slowly, but when I did examine the final 
oocyte I felt as much excitement as I had ever experienced in my life. Excitement 
beyond belief.  A living, ripening, human egg, unbombarded by any hormones, 
beginning its programme just as the mouse eggs had done. There, in one egg, in 160 
the last of the group, lay the whole secret of the human program.” (Edwards and 
Steptoe, 1980). 
 
Edwards went on to determine that MII is reached at 36 hours in human IVM oocytes. He 164 
also demonstrated that complete spontaneous oocyte maturation could be achieved in various 
and disparate species (mice, pigs, cows, sheep, rhesus monkey and human), so long as 
sufficient maturation time was allowed, demonstrating the universality of this concept 
(Edwards, 1965b).  His comparative reproductive biology approach in both papers was 168 
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important and insightful as he understood that reliance on one model only (i.e. the mouse) 
may not provide the answers he required to enable reliable IVM for production of embryos in 
the human.  This was his primary goal. 
 172 
From this point onwards, Edwards turned his attention to attempting to fertilise the IVM MII 
oocytes.  After a number of years attempting to capacitate human sperm, including in vivo in 
reproductive tracts of a range of species, he returned to in vitro approaches. At this stage he 
had recruited Barry Bavister to his lab to work on media for IVF. Bavister’s experience with 176 
developing hamster IVF with ‘Bunny’ Austin proved decisive, as adapting those techniques 
and using their own sperm, in March 1968 they eventually successfully fertilised a human 
oocyte in vitro (Bavister et al., 1969; Edwards et al., 1969). Notably both these papers used 
human IVM oocytes collected from unstimulated ovaries and matured in vitro for 36-37 180 
hours in a mixture of three parts follicular fluid and one part “Bavister’s medium”.  At this 
time Edwards sought out a clinical partner and subsequently teamed up with Patrick Steptoe. 
From this point onwards, Edwards was immersed in the world-wide race to achieve the first 
IVF pregnancy and he never returned to IVM research. Notably, despite his expertise and 184 
successes with IVM, he incisively turned to in vivo matured oocytes for the IVF program. He 
justified this decision on the basis that, at the time, embryonic development from IVM animal 
oocytes was poor. This was an astute observation and this is an ongoing issue for IVM today 
(see below).  While major advances continued in animal IVM which led to the first 188 
pregnancies from IVM mouse oocytes (Cross and Brinster, 1970), human IVM took a back 
seat to hyperstimulated IVF, and it was not until much later in 1991 that the first human IVM 
child was born from an unstimulated cycle (Cha et al., 1991).  
 192 
Insights from the 1960’s that remain relevant to the challenges in clinical IVM today 
 
In many respects, clinical practice of human IVM has changed little since the 1960’s.  
Spontaneous maturation of oocytes following recovery from medium sized antral follicles (6-196 
10 mm) continues to this day.  Furthermore, the base media formulation used has not altered 
in four decades.  We propose that there are six main challenges for clinical IVM today: 
1. To increase the recovery rate of immature COCs from follicles of unstimulated 
ovaries, 200 
2. To increase the meiotic maturation rate of IVM oocytes, 
3. To increase the developmental competence of IVM oocytes, 
7 
 
4. To determine whether any in vivo ovarian stimulation is desirable and if so which 
stimulation regime, 204 
5. To establish a clinical IVM protocol that supports adequate endometrial development 
and receptivity, 
6. To further verify the safety of IVM by conducting detailed follow up studies on the 
health of IVM offspring.  208 
In the following sections, we will discuss concepts that emerged from Edwards’ work and 
from that period, that remain relevant to some of these current challenges. 
 
Oocyte meiotic competence: 212 
 
It is highly noteworthy that Edwards reported a MII rate for human IVM of approximately 50% 
(Edwards, 1965b). This is similar to the earliest descriptions of human IVM by Pincus and 
Saunders (Pincus and Saunders, 1939). Despairingly to investigators currently working in the 216 
field, the efficiency of maturation of human IVM oocytes to MII essentially has not improved.  
Maturation rates of ~50 – 60% are still the norm today.  Edwards reported high rates of 
oocyte maturation from IVM in mice, sheep and cows, but lower rates (<50%) in pig, rhesus 
and human oocytes.  This is largely consistent with the literature today, where in particular, 220 
the low MII rate in human IVM remains a major obstacle to the efficiency of the technology 
and therefore to the clinical uptake of the approach. 
 
Cytoplasmic maturation in vitro and oocyte competency: 224 
 
Edwards was working on IVM at a time when the concept of oocyte cytoplasmic maturity 
was emerging. The concept was first used to describe the capacity for DNA replication and 
cleavage of amphibian eggs.  By the 1970’s, it was widely described that oocyte maturation 228 
could be divided into nuclear maturation and cytoplasmic maturation, whereby meiotically 
mature oocytes may not necessarily have undergone complete cytoplasmic maturation. When 
applied to mammalian oocytes, unfortunately the term cytoplasmic maturation has multiple 
meanings depending on the context.  For example, oocyte cytoplasmic maturation can be 232 
used to describe ultrastructural features of the oocyte, including movement of organelles 
during nuclear maturation.  It has been used to describe the capacity of the ooplasm to enable 
complete meiotic maturation, e.g. as a function of oocyte growth.  But most commonly, 
cytoplasmic maturation was thought to encompass the oocyte’s capacity for subsequent 236 
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development. More recently, oocyte cytoplasmic maturation is termed “oocyte capacitation” 
(Hyttel et al., 1997) or “oocyte developmental competence”, describing “the biochemical and 
molecular state that allows a mature oocyte to be fertilized normally and develop to an 
embryo, which on transfer will enable development to term.” (Gilchrist and Thompson, 2007).  240 
This clearly encompasses an enormous field of cell biology and explains why it has proved so 
elusive, but nevertheless, an appreciation of the hallmarks of oocyte developmental 
competence is emerging.   
 244 
By the mid-1960’s Robert Edwards was acutely aware of the concept of oocyte 
developmental competence, even if the terminology did not exist. Although the results of his 
1965 paper focused entirely on oocyte meiotic competence and meiotic kinetics, his insight 
extended to the possible role of accumulated mRNA within oocytes having an impact on 248 
subsequent embryo development.  He noted that synthesis of RNA and “initiation of 
heterochromatin” in the oocyte during the pre-ovulatory period might be important (Edwards, 
1965b). This of course has proved entirely accurate and lies not only at the heart of oocyte 
developmental competence but also in the concept of the developmental origins of adult 252 
health having its origins in appropriate epigenetic programming of the developing immature 
oocyte and early embryo. His prediction is particularly poignant, as it reveals he appreciated 
the importance of the oocyte’s legacy to embryo development, as he concluded that oocytes 
maturing in vivo are more competent for further development than IVM matured oocytes 256 
(Edwards et al., 1969).  This mismatch in competency remains a defining limitation of the 
IVM-derived oocyte (Gilchrist et al., 2011; Gremeau et al., 2012). An important area of 
future research is to determine if the lower competence of IVM oocytes affects the health of 
IVM offspring. This area of research is made more difficult by the relatively few IVM 260 
children born so far, but the follow-up studies to date are encouraging in that no major 
increased health risks have been reported (Shu-Chi et al., 2006; Soderstrom-Anttila et al., 
2006; Buckett et al., 2007). Likewise, follow-up studies on mice IVM offspring suggest there 
is no major cause for concern (Eppig et al., 2009), but nonetheless, more animal and clinical 264 
research is needed in this area. 
 
Oocyte developmental competence is largely acquired in vivo during the antral phase of 
folliculogenesis.  However, this competence can be readily “lost” using inappropriate IVM 268 
conditions. Edwards appreciated the critical importance of IVM culture conditions to the 
health of the oocyte. His IVM papers give truly insightful suggestions for improving IVM, 
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which in subsequent years, were shown by others to significantly impact oocyte 
developmental competence across several species, including human.  For example, in both 272 
papers he experimented with different base media, especially tissue culture medium-199 
(TCM199), but also Waymouth’s media.  Today, TCM199 with Earles’ salts remains the gold 
standard in IVM across several species, including widespread commercial application in 
cattle and human IVM.  Furthermore, described within the text of the 1962 and 1965 Nature 276 
papers is an array of culture condition variables he experimentally tested to determine if they 
had an impact on oocyte maturation.  These included: incubation with supplemental serum, 
follicular fluid, feeder cell monolayers; varying atmospheric gas composition; addition of 
antioxidants (reduced glutathione and ascorbic acid); addition of vitamins (folinic acid, a 280 
vitamer for folic acid, and ascorbic acid) and addition of ATP directly to cultures, in addition 
to other ideas (Edwards, 1965b).  Although the details of what was attempted presumably 
remains within his laboratory books, the judgement to assess such factors was, in hindsight, 
years ahead of his time as many of these remain pertinent questions to the improvement of 284 
IVM nuclear maturation and developmental competence nearly half a century later. 
 
Pincus, Chang and Edwards all separately noted that oocytes remain at the GV stage when 
retained within their follicle, whether in vivo or explanted. They correctly concluded that the 288 
follicle is inhibitory to oocyte maturation and that oocytes will spontaneously resume meiosis 
when liberated from the follicle. One theory that emerged to improve cytoplasmic maturation 
of fully grown oocytes during IVM was to delay the spontaneous maturation process that 
Edwards and others had described.  In the mouse, several approaches were found to inhibit 292 
GVBD during IVM. Wassarman et al (Wassarman et al., 1976) demonstrated that addition of 
dibutryl cAMP was effective at preventing GVBD in mouse oocytes, reflecting the major role 
cAMP has in arresting meiosis in vivo.  Inhibition of GVBD was found to occur by inhibiting 
protein synthesis (cycloheximide) or by use of kinase inhibitors (DMAP, roscovitine, 296 
butyrlactone) that target specific cell-cycle regulatory kinases.  These treatments can be very 
effective at preventing oocyte meiosis in vitro, but collectively all have been found to 
negatively affect subsequent development (including of human oocytes; (Anderiesz et al., 
2000)), demonstrating that inhibiting such proteins directly involved in meiosis is not a sound 300 
strategy.  By contrast, follicular somatic cell factors that have been identified as the natural 
mediators of oocyte meiotic arrest (i.e. the natriuretic peptides and their downstream effectors; 
cGMP and cAMP) have been successfully used in IVM in animal species to control 
spontaneous meiosis during IVM, as a means to improve oocyte competence (reviewed; 304 
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(Gilchrist, 2011; Smitz et al., 2011)). The limited number of studies to date show promising 
results using human IVM oocytes (Nogueira et al., 2006; Shu et al., 2008). 
 
Clinical IVM protocols:  308 
 
Edwards’ pioneering studies on human IVM were all conducted using oocytes collected from 
unstimulated ovaries or pieces of ovaries collected from gynaecological surgeries (Edwards, 
1962; Edwards, 1965b; Edwards et al., 1969). As a source of oocytes, this parallels what is 312 
currently used with high success in ruminant animal IVM laboratories for producing embryos 
from abattoir-derived ovaries. However, over the past two decades, attempts to improve 
human IVM have transgressed into an array of in vivo hormonal interventions.  A wide range 
of clinical protocols exist, including: no stimulation; short duration follicle stimulation 316 
hormone (FSH)-priming; hCG-priming; and FSH and hCG stimulation which may more 
appropriately be called ”short-stim IVF”. Protocols derived by SL Tan and colleagues at 
McGill University recommended an “hCG-priming” regime of a single large bolus of hCG 
(10,000 IU), approximately 36 hours prior to oocyte recovery (Chian et al., 1999). The result 320 
is mostly a mixture of 1-2 oocytes with expanded cumulus and undergoing meiotic 
progression, and usually a larger cohort of recovered oocytes with compact cumulus, most of 
which had not undergone GVBD.  A greater proportion of embryos per oocyte retrieved 
invariably were associated with the activated follicular oocytes.  A consequence of this 324 
regimen is the need for multiple rounds of intracytoplasmic sperm injection per cycle, as 
timing of meiotic completion to MII varies markedly.  This protocol has been widely used by 
IVM clinics throughout the 1990s and 2000s, although a number of more recent randomised 
trials have shown no benefit in overall pregnancy establishment over hormone-free IVM 328 
(Fadini et al., 2009; Zheng et al., 2012). A trend is emerging within the human IVM field to 
move back to the more traditional definition of IVM (i.e. in vitro maturation of immature 
COCs), either from unstimulated patients or patients mildly stimulated with 1-3 days of FSH.  
The question of patient preparation remains a vitally important one in IVM and an important 332 
area of clinical research. 
 
Concluding remarks  
 336 
Robert Edwards conducted groundbreaking IVM research, published in a series of seminal 
papers that paved the way for the development of a reproductive technology that today 
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generates millions of embryos and pregnancies annually across a wide array of species.  In 
women, it promises fertility preservation as well as simple, safe and cheaper infertility 340 
treatment, without the need for patient hormonal stimulation. IVM was instrumental in 
Edwards’ major advances in reproductive medicine.  He remained a passionate advocate of 
IVM throughout his life and in the twilight of his career he published a review entitled “Are 
minimal stimulation IVF and IVM set to replace routine IVF?” (Edwards, 2007).  Time will 344 
tell and it remains to be determined if Edwards’ enormously successful approach of 
translating breakthroughs from animal research to revolutionary clinical medicine, can be 
sustained in the modern era, to increase the uptake of clinical IVM. 
 348 
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